Take One: Big story of the day
-
Havells: Punching above its weight, and winning
How Anil Rai Gupta's Havells is battling MNCs by aggressively unleashing its manufacturing prowess in consumer durables
-
SaaS startups: India-born, US-focussed
Strong cloud-based enterprise software product companies are emerging in India, but are quickly moving to the US, drawn by customers, ecosystem and the IPO dream
-
How Route Mobile became a darling of investors
The cloud communications platform provider which started with an investment of $2,000 in 2004 and a second-hand computer, has seen its stock listed at an 86% premium, and has risen over 92% over the past two months
-
How India's boAt became the fifth largest wearable brand in the world
The inside story of how boAt, a homegrown consumer electronics upstart, took the wind out of the sails of foreign wearables giants
-
How Bata's Sandeep Kataria clinched the global CEO post
He becomes the first Indian to hold the position in the company's 126-year history. Now, he'll need to replicate successful strategies across global markets as growth is likely to pick-up in mid-2021
-
Inside India's Covid-19 vaccine trials: The volunteers' story
Volunteers who took the jab give Forbes India a peek into their apprehensions and the aftermath
-
Testing company Kilpest: Valuing a sudden bump in profitability
An unexpected and extraordinary development at Kilpest left investors grappling with a question: How does one value an extraordinary surge in profits?
-
Farm acts: Are the reforms necessary?
Ahead of the farmer-led Bharat Bandh tomorrow, we speak to farmers on-ground to understand the way forward, and why they will continue to stand their ground
-
Covid-19 vaccine trials: How much information is too much information?
As the Serum Institute moves towards seeking emergency-use authorisation of its vaccine candidate, experts talk about navigating the grey area of deciding how much information around the clinical trials needs to be made public in order to retain people's trust in the process
-
We can be 100% transparent with Covid-19 trials, but that will have very low utility value: Dr Gagandeep Kang
The virologist and fellow of the Royal Society of London speaks to Forbes India about transparency in clinical trials, emergency use authorisation for a Covid-19 vaccine candidate in India and whether the vaccine should be available for sale in the private market. Edited excerpts
-
Mahashay Dharampal Gulati: How a horse-cart driver became India's spice king with MDH
A man ahead of his time, the ever-smiling nonagenarian who passed away on Thursday, built an enviable brand and ended up becoming the highest-paid CEO in the FMCG sector in India in 2017